Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia.

Sanjay K BajpaiM Janelle Cambron-MellottOliver WillJiat-Ling PoonQianqian WangBeth D MitchellEugenia Y PeckJane BabrowiczNedina K RaibuletChristopher J ChildKathleen Beusterien

Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2022)

This study supports the validity and reliability of the GDAQ, which successfully conceptualizes attitudes towards devices for administering glucagon among different respondent groups. Use of the GDAQ can help guide the development and testing of new glucagon drug/device combinations.

Keyphrases

type diabetes
early onset
drug induced
adipose tissue
skeletal muscle